These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34955159)

  • 21. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
    Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
    Moore KN; Pothuri B
    Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
    Richardson DL; Eskander RN; O'Malley DM
    JAMA Oncol; 2023 Jun; 9(6):851-859. PubMed ID: 37079311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Not Available].
    Pautier P; Kalbacher E; de la Motte Rouge T; Bonnetain F; Lesoin A
    Bull Cancer; 2017 May; 104 Suppl 1():S32-S38. PubMed ID: 28625313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?
    Turinetto M; Ray-Coquard I; Gourley C
    ESMO Open; 2024 May; 9(5):102983. PubMed ID: 38663167
    [No Abstract]   [Full Text] [Related]  

  • 28. The systemic treatment of recurrent ovarian cancer revisited.
    Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
    Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
    Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
    Zhao Q; Ni J; Dong J; Cheng X; Xiao L; Xue Q; Xu X; Guo W; Chen X
    Reprod Sci; 2023 Feb; 30(2):615-621. PubMed ID: 35943701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
    Harter P; Pautier P; Van Nieuwenhuysen E; Reuss A; Redondo A; Lindemann K; Kurzeder C; Petru E; Heitz F; Sehouli J; Degregorio N; Wimberger P; Burges A; Cron N; Ledermann J; Lorusso D; Paoletti X; Marme F
    Int J Gynecol Cancer; 2020 Dec; 30(12):1997-2001. PubMed ID: 32606097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PARP inhibition as frontline therapy in ovarian cancer.
    Moore KN; Pothuri B; Monk B; Coleman RL
    Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current post-surgical treatment strategies in first-line ovarian cancer].
    Ouali K; Michels J; Blanc-Durand F; Leary A; Kfoury M; Genestie C; Morice P; Zaccarini F; Scherrier S; Gouy S; Maulard A; Pautier P
    Bull Cancer; 2024 Mar; 111(3):267-276. PubMed ID: 36863923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review.
    Gadducci A; Cosio S
    Anticancer Res; 2021 Oct; 41(10):4673-4685. PubMed ID: 34593415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in
    Lee YJ; Lim MC; Kim BG; Ngoi NY; Choi CH; Park SY; Tan DS; Go Y; Lee JY
    J Gynecol Oncol; 2021 Mar; 32(2):e31. PubMed ID: 33559413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of niraparib for the treatment of ovarian cancer.
    Ethier JL; Lheureux S; Oza AM
    Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    Washington C; Gunderson CC; Moore KN
    Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB
    Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.